Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A comparison of Symbicort single inhaler therapy (Symbicort 200 Turbohaler 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults-a 26-week, randomised, open-label, parallel group, multicentre study,

X
Trial Profile

A comparison of Symbicort single inhaler therapy (Symbicort 200 Turbohaler 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults-a 26-week, randomised, open-label, parallel group, multicentre study,

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2009

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms SOLO
  • Sponsors AstraZeneca
  • Most Recent Events

    • 13 Oct 2009 Actual end date (Oct 2005) added as reported by ClinicalTrials.gov.
    • 11 Jan 2008 Status changed from in progress to completed.
    • 22 Dec 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top